Patents Assigned to Chugai Pharmaceutical Co.
-
Patent number: 11104668Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: December 10, 2014Date of Patent: August 31, 2021Assignees: Hoffmann-La Roche Inc., Chugai Pharmaceutical Co.Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
-
Patent number: 10093657Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: March 9, 2017Date of Patent: October 9, 2018Assignees: HOFFMANN-LA ROCHE INC., CHUGAI PHARMACEUTICAL CO.Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
-
Patent number: 9624201Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: December 10, 2014Date of Patent: April 18, 2017Assignees: HOFFMANN-LA ROCHE INC., CHUGAI PHARMACEUTICAL CO.Inventors: Francisco Javier Lopez-Tapia, Sung-Sau So, Qi Qiao, Romyr Dominique
-
Patent number: 9556150Abstract: This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.Type: GrantFiled: December 10, 2014Date of Patent: January 31, 2017Assignees: Hoffmann-La Roche Inc., Chugai Pharmaceutical Co.Inventors: Francisco Javier Lopez-Tapia, Norman Kong, Sung-Sau So, Yan Lou, Romyr Dominique
-
Patent number: 9057727Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: September 25, 2013Date of Patent: June 16, 2015Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Publication number: 20140086842Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicants: Chugai Pharmaceutical Co., Ltd., The General Hospital CorporationInventors: Thomas J. GARDELLA, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Patent number: 8568737Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Publication number: 20110172153Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: August 1, 2008Publication date: July 14, 2011Applicants: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 6068840Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: July 29, 1997Date of Patent: May 30, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6048972Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: June 20, 1997Date of Patent: April 11, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 6024956Abstract: Monoclonal antibodies immunospecific for the neutrophil chemotactic factor, IL-8, have been humanized by reshaping the variable regions to conform more closely to human counterparts. These antibodies are useful in immunoassays to detect IL-8 and as ligands on immunoaffinity columns for purification of human IL-8. In addition, the humanized antibodies have an antiinflammatory effect in patients.Type: GrantFiled: August 29, 1997Date of Patent: February 15, 2000Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Kouji Matsushima, Yoshihiro Matsumoto, Yoshiki Yamada, Koh Sato, Masayuki Tsuchiya, Tatsumi Yamazaki
-
Patent number: 5968784Abstract: The present invention provides novel methods for identifying gene expression patterns in mRNA populations. The methods are useful for determining differential gene expression among various cells or tissues, including cells or tissues of a target organism. The invention also provides methods of determining the frequency of gene expression in mRNA populations, thus providing a method of comparing gene expression frequency among various cells or tissues. The present invention also provides methods for isolating genes corresponding to tag sequences identified according to the methods of the present invention. Furthermore, sequences that are identified according to the present invention may be used to diagnose the presence of disease.Type: GrantFiled: January 15, 1997Date of Patent: October 19, 1999Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Dominic G. Spinella, Fereydoun G. Sajjadi
-
Patent number: 5866341Abstract: A method of screening for binding partners of a specific molecule. The method employs a chimeric protein having at least two different binding regions; one containing at least a portion of the specific molecule or an analog thereof, and the other containing a binding region of an immunoglobulin chain. In a preferred embodiment, the method is used for rapidly screening member compounds of a combinatorial library for potential biological activity.Type: GrantFiled: April 3, 1996Date of Patent: February 2, 1999Assignee: Chugai Pharmaceutical Co., Ltd.Inventors: Dominic Gregory Spinella, Kathleen Ann Becherer, Steven Joel Brown
-
Patent number: 5707621Abstract: A method for ameliorating at least one of the symptoms of nephritis is disclosed. Administration of antibodies or immunologically reactive fragments thereof which are immunoreactive with the IL-8 of the subject suppresses the elevated excretion of protein and infiltration of neutrophils associated with this condition.Type: GrantFiled: August 31, 1994Date of Patent: January 13, 1998Assignee: Chugai Pharmaceutical Co., Ltd.Inventor: Kouji Matsushima
-
Patent number: 5464828Abstract: The invention is an aqueous suspension of sucralfate (sucrose sulfate aluminum salt), which is added with a starch and/or a derivative thereof and preferably further with a cellulose derivative, polysaccharide gum, alginic acid, alginate and/or bentonite, whereby the suspension is made stable for a long time and may be redispersed if necessary. The invention can thus provide a liquid pharmaceutical preparation useful for protecting ulcer areas on mucous membranes of the stomach and duodenum industrially for the first time, although solid pharmaceutical preparations have been available.Type: GrantFiled: January 24, 1994Date of Patent: November 7, 1995Assignees: Chugai Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd.Inventors: Masahide Katayama, Harushige Yamashita, Taizo Okada, Shigeo Morioka